prt3789
·Code: PRT3789
prt3789: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Prelude Therapeutics Inc (PRLD) | Phase 1 |
Clinical Trials (1)
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Frequently asked questions
Who is developing prt3789?
prt3789 is being developed by Prelude Therapeutics Inc.
How many clinical trials involve prt3789?
BioSniper tracks 1 clinical trial involving prt3789.
Get deeper analysis on prt3789
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis